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Serotonin (5-HT) is a hormone and neurotransmitter that modulates neural activity as well
as a wide range of other physiological processes including cardiovascular function, bowel
motility, and platelet aggregation. 5-HT synthesis is catalyzed by tryptophan hydroxylase
(TPH) which exists as two distinct isoforms; TPH1 and TPH2, which are responsible for
peripheral and central 5-HT, respectively. Due to the implication of 5-HT in a number of
pathologies, including depression, anxiety, autism, sexual dysfunction, irritable bowel
syndrome, inflammatory bowel disease, and carcinoid syndrome, there has been a
growing interest in finding modulators of these enzymes in recent years. We thus
performed high-throughput screening (HTS) using a fluorescence-based thermal shift
assay (DSF) to search the Prestwick Chemical Library containing 1,280 compounds,
mostly FDA-approved drugs, for TPH1 binders. We here report the identification of
omeprazole, a proton pump inhibitor, as an inhibitor of TPH1 and TPH2 with low
micromolar potency and high selectivity over the other aromatic amino acid
hydroxylases. The S-enantiomer of omeprazole, esomeprazole, has recently also been
described as an inhibitor of monoamine oxidase-A (MAO-A), the main enzyme responsible
for 5-HT degradation, albeit with lower potency compared to the effect on TPH1 and
TPH2. In order to investigate the net effect of simultaneous inhibition of TPH and MAO-A in
vivo, we administered high-dose (100 mg/kg) omeprazole to CD-1 mice for 4 days, after
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and peripheral (serum) 5-HT content was measured using liquid chromatography-mass
spectrometry (LC-MS). Omeprazole treatment significantly increased 5-HT
concentrations, both in brain and in serum, and reduced the time spent immobile in
the tail suspension test relative to vehicle control. Thus, the MAO-A inhibition afforded by
high-dose omeprazole appears to overcome the opposing effect on 5-HT produced by
inhibition of TPH1 and TPH2. Further modification of proton pump inhibitor scaffolds may
yield more selective modulators of 5-HT metabolism.
Keywords: serotonin, drug repurposing, high-throughput screening assay, molecular docking analysis, enzyme
assay, allosteric site
INTRODUCTION
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine
neurotransmitter, synthesized mainly in the enterochromaffin
cells of the gut and the raphe nuclei of the central nervous system
(CNS). 5-HT is implicated in the control of a wide variety of
physiological functions in the CNS and the peripheral nervous
system (PNS), such as sleep, pain, gut motility, appetite, sexual
behavior and mood, insulin secretion, and heart and brain
development (Cote et al., 2007; Berger et al., 2009). The key
enzymes that promote the biosynthesis and degradation of 5-HT
are the tryptophan hydroxylases (TPHs) (McKinney et al., 2005)
and monoamine oxidase (MAO) (Tong et al., 2013), respectively.
The TPHs catalyze the first and rate limiting step of the
biosynthesis of 5-HT starting from the amino acid, tryptophan
and are encoded by two different genes; TPH1, which is
responsible for the synthesis of 5-HT in peripheral tissues and
the pineal gland, and TPH2, which is the main source of 5-HT in
CNS tissues (Walther and Bader, 2003; Walther et al., 2003).
Monoamine oxidases (MAOs) are flavin adenine dinucleotide
(FAD) co-factor-dependent enzymes involved in the regulation
of neurotransmitter levels in both peripheral and central tissues
(Slotkin, 1999; De Colibus et al., 2005). The MAOs exist as two
distinct isoforms, MAO-A and MAO-B, which share highly
conserved features, but are expressed in different cell types
and exhibit different regulatory properties and substrate
specificities (Zhang et al., 2019). The MAO-A isoform controls
5-HT catabolism by catalyzing its oxidation to 5-
hydroxyindoleacetic acid and is important for maintaining
physiological 5-HT levels in various tissues (Tong et al., 2013).
Both TPHs and MAO-A are thus attractive targets for
treatment of disorders linked to the dysregulation of 5-HT
levels either in the CNS or PNS. Several TPH1 inhibitors have
been developed for treating diseases associated with elevated 5-
HT levels in peripheral tissues such as carcinoid syndrome,
irritable bowel disease with diarrhea, inflammatory bowel
disease, pulmonary arterial hypertension, obesity, and diabetes
(Manocha and Khan, 2012; Margolis et al., 2014; Kim et al., 2015;
Waloen et al., 2017; Matthes and Bader, 2018); e.g.,
p-chlorophenylalanine (fenclonine, pCPA) (Engelman et al.,
1967), which was the first TPH inhibitor to reach clinical
studies. However, due to the occurrence of depression as a
side effect, the clinical development of this compound was
discontinued (Zimmer et al., 2002). TPH inhibitor-induced
depression is likely a result of TPH2 inhibition and
consequent reduction of central 5-HT. Hence, the
development of TPH1 inhibitors which cannot cross the
blood–brain barrier remains an appealing challenge to
medicinal chemists. With a peripheral action in mind,
derivatives of pCPA, e.g.; LP-521834, LP-534193, and LP-
533401, have been developed as TPH1 inhibitors by Lexicon
Pharmaceuticals (Cianchetta et al., 2010), whereas other
compounds including KAR5585 and KAR5417, have been
synthesized by Karos Pharmaceuticals for the same target
(Goldberg et al., 2017). Few of these compounds have reached
clinical studies; as of today, only telotristat ethyl (LX-1032),
developed by Lexicon, has received FDA approval for
treatment of carcinoid syndrome (Markham, 2017). The two
other members of the aromatic amino acid hydroxylase family,
tyrosine hydroxylase (TH) and phenylalanine hydroxylase
(PAH), share a highly conserved active site with TPH1 and
TPH2 (Teigen et al., 2007). Novel TPH1 inhibitors with
improved selectivity over tyrosine hydroxylase (TH) and
phenylalanine hydroxylase (PAH) would therefore be desirable
in order to reduce undesired effects on the metabolism of other
monoamines.
Increased MAO-A activity has been associated with
depression (Meyer et al., 2006) and several FDA-approved
MAO-A inhibitors have been used for the treatment of
depression and anxiety (Finberg and Rabey, 2016). Among
these inhibitors, iproniazid was first described in 1983 by
Lehmann and Kline for treating depression (Sandler, 1990).
Likewise, several non-subtype-selective, irreversible MAO
inhibitors were developed from this compound; e.g.,
tranylcypromine, which is used clinically as an antidepressant
despite causing potentially serious “cheese effect” adverse
reactions, precipitating episodes of high blood pressure upon
intake of foods rich in tyramine, including some aged cheeses
(Gillman, 2011). Another serious and sometimes lethal adverse
effect documented among patients taking MAO inhibitors is
serotonin syndrome, typically including neuromuscular and
autonomic hyperactivity (such as tremor and fever) and
agitation. Serotonin syndrome may be triggered when
combining MAO inhibitors with serotonergic drugs such as
selective serotonin reuptake inhibitors (SSRIs) (Gillman, 2006).
Therapeutic targeting of 5-HT dysregulation remains a
challenge in drug discovery, since 5-HT signaling is involved
in a wide spectrum of biological functions in the human body.
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Safety and selectivity are thus important issues to be considered
before the drug candidate reaches clinical trials. Attempts at
repositioning of already FDA-approved drugs for novel
indications have increased rapidly in recent years. The
potential value of this strategy lies in the reduction of the time
and economic risk typically associated with bringing new drug
candidates to clinical trials (Keiser et al., 2009; Corsello et al.,
2017). Furthermore, screening approved drugs for unknown off-
targets may reveal valuable information regarding adverse
reactions associated with their use (Keiser et al., 2009). Here,
we used a high-throughput screening (HTS) in vitro assay based
on differential scanning fluorimetry (DSF) in order to find TPH1
binders among the mostly (95%) FDA-approved compounds of
the Prestwick Chemical Library (1,280 substances).
Results showed that the best-selling, over-the-counter proton
pump (H+/K+-ATPase) inhibitor, omeprazole, inhibited TPH1
and TPH2 in the low micromolar range and displayed excellent
selectivity over the other closely related aromatic amino acid
hydroxylases, i.e.; TH and PAH. Proton pump inhibitors are used
clinically for the treatment of gastroesophageal reflux disease and
peptic ulcer disease (Herszenyi et al., 2020). These compounds are
prodrugs which are absorbed from the gastro-intestinal tract and
converted into their active sulfonamide form, which irreversibly
binds and inhibits H+/K+-ATPase, in the acidic canaliculi of the
gastric parietal cells (Howden, 1991). Proton pump inhibitors are
sold without prescription in many countries and are considered
among the safest classes of drugs, generally being well tolerated.
Interestingly, the S-enantiomer of omeprazole; esomeprazole, was
recently reported to inhibit MAO-A (Petzer et al., 2013). In order
to gainmore insight into the serotonergic profiles of proton pump
inhibitors, we characterized the inhibitory effects of omeprazole,
esomeprazole, and their commercially available analogues on
TPH1 and TPH2. The activities of omeprazole and its
analogues at MAO-A were also assessed. Finally, the effect of




The Prestwick Chemical Library was purchased from Prestwick
Chemical labs (Paris, France). SYPRO Orange, reagents and
compounds were purchased from Sigma-Aldrich (St. Louis,
MO, USA) with a purity of at least 95%. Chromatography
materials for enzyme purification and enzymatic activity assay
were purchased from Amersham Biosciences, GE Healthcare
(Chicago, IL) 6R-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4)
was purchased from Schircks Laboratories (Bauma, Switzerland).
The ΔNH102-ΔCOOH402 human TPH1 gene was cloned into
the pET23a vector (six-His C-terminal fusion; Merck KGaA,
Darmstadt, Germany) between the NdeI and XhoI restriction
sites, and expressed and purified as described previously (Wang
et al., 2002; Betari et al., 2020). Truncated TPH1 was used since
the full-length enzyme tends to aggregate in bacteria and yeast
extracts and during purification (Wang et al., 2002; McKinney
et al., 2005), resulting in a much lower protein yield compared to
the truncated version. Enzymatic activity of truncated TPH1 is
equal to that of the full-length protein (Betari et al., 2020). For
comparison, full-length TPH1 was used as a control in a subset of
experiments with omeprazole.
Full-length WT TPH1 and TPH2 were expressed as
N-terminal six-His-maltose-binding protein fusion proteins in
pETM-41 and were cleaved and purified as described previously
(McKinney et al., 2004;Winge et al., 2007). HumanWT PAH and
TH were expressed and isolated as described previously (Flydal
et al., 2012; Bezem et al., 2016).
Differential Scanning Fluorimetry Assay
Human doubly truncated TPH1 (ΔNH102-ΔCOOH402) was used
for HTS using the DSF method (a fluorescence-based thermal
stability assay) (Lo et al., 2004; Niesen et al., 2007). The protein
was overexpressed, purified and stored in 20 mM Na HEPES
(sodium salt of HEPES, pH 7.0), 200 mM NaCl as previously
described (Wang et al., 2002; Betari et al., 2020).
The Prestwick Chemical Library, which consists of 1,280 small
molecules (95% FDA-approved drugs), was screened using the
DSF method. The compound stocks were prepared at a
concentration of 10 mM in DMSO. SYPRO Orange was
utilized at 1,000x dilution to monitor protein unfolding using
a Lightcycler 480 Real-Time PCR System (Roche Applied Science,
Penzberg, Germany), using the 384 well format. The enzyme was
diluted in 20 mM Na HEPES, 200 mM NaCl (pH 7.0) buffer to a
final concentration of 0.075 mg/ml and compounds were added
to a final concentration of 200 μM. Control experiments with 2%
DMSO were performed in the absence of ligand on each 384-well
plate. Next, samples were incubated at room temperature for
30 min before measurements were started on the Lightcycler®
480 Real-Time PCR System. The thermal shift curves were
recorded in the presence and absence of the compounds from
20°C to 95°C with four acquisitions per °C, including a 10 s hold at
20°C before and after the experiment. Part of the results of the
DSF screen have been presented previously.
Tryptophan HydroxylaseEnzymatic Activity
Assay
Enzymatic activity assays were performed with selected hits from
the DSF screen in the presence or absence of 100 µM of tested
compound. Control experiments were performed in the presence
of 1% DMSO in the absence of ligand. TPH1 activities were
assayed at 37°C in a standard reaction mixture (100 µL final
volume) containing 40 mM Na HEPES, 0.05 mg/ml catalase,
10 µM ferrous ammonium sulfate, and 20 μM L-tryptophan
(L-Trp). The enzymatic reaction was initiated by adding
200 μM BH4 and 2 mM DTT (final concentrations) and
stopped by precipitation with 2% (v/v) acetic acid in ethanol.
5-hydroxy tryptophan (5-OH-Trp) was quantified using High
Performance Liquid Chromatography (HPLC) essentially as
described previously with minor modifications (McKinney
et al., 2004; Winge et al., 2007; Betari et al., 2020).
Compounds inhibiting TPH1 activity by more than 50% in
the preliminary activity assay were selected for further dose-
response analyses and IC50 determination. The effect of
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omeprazole and its analogues were determined on both the
doubly truncated TPH1 protein and WT full-length TPH2
protein. The effect of omeprazole was also studied at full-
length WT TPH1.
Mechanism of Action and Kinetics Analysis
of Omeprazole
The mode of TPH1 inhibition by omeprazole was investigated
using doubly truncated TPH1 (ΔNH102-ΔCOOH402) as
described previously (Betari et al., 2020). The TPH1 activity
assay was performed as indicated above in the absence and
presence of omeprazole (1, 10, or 100 µM). 5-OH-Trp
formation was measured either at a fixed concentration
(200 µM) of the cofactor, BH4, and varying concentrations
(0.625–20 µM) of the substrate, L-Trp, or in the presence of
varying concentrations of BH4 (2.4–200 µM) and a fixed
concentration (20 µM) of L-Trp. Kinetic parameters were
estimated by fitting the Michaelis-Menten model to the data
using nonlinear regression.
Selectivity Studies of Omeprazole –
Enzymatic Activity Assays Using Other
Aromatic Amino Acid Hydroxylases
The selectivity of omeprazole for inhibiting TPH1 over the other
aromatic amino acid hydroxylases; TPH2, TH, and PAH, was
investigated using in vitro functional enzyme assays. PurifiedWT
human TPH2, PAH, and TH were used for this purpose, and the
activity assays for each enzyme was performed as described
previously (Haavik and Flatmark, 1980; Winge et al., 2007;
Aubi et al., 2015; Bezem et al., 2016).
Monoamine Oxidase-A Enzymatic Activity
Assay
The effects of omeprazole and its analogues on MAO-A activity
were determined using a commercial MAO-A Inhibitor
Screening Kit. The experiments were conducted following the
manufacturer’s (BioVision, Inc, Milpitas, CA) instructions and
were based on the fluorimetric detection of H2O2, a byproduct of
the enzymatic activity of MAO-A, by measuring the fluorescence
(Excitation/Emission at 535/587 nm) kinetically at 25°C for
15 min using a Tecan Spark plate reader (Tecan Group Ltd,
Männedorf, Switzerland).
Molecular Docking
Molecular docking was performed with Glide which is part of the
Schrodinger program package (Schrödinger release 2020–1:
Glide, Schrödinger, LLC, New York, NY, 2020). The “Induced
Fit Docking” (IFD) protocol (Schrödinger release 2020–1:
Induced Fit Docking protocol; Glide, Schrödinger, LLC, New
York, NY, 2016; Prime, Schrödinger, LLC, New York, NY, 2020)
was used to flexibly dock omeprazole into MAO-A and TPH1.
Four forms of omeprazole were prepared for docking, i.e., the S
and R enantiomers as well as protonated and neutral forms.
Coordinates used for docking were those of human MAO-A in
complex with harmine (PDB identification code 2Z5X (Son et al.,
2008); and human TPH1 in complex with its biopterin cofactor
(PDB identification code 1MLW) (Wang et al., 2002). Sidechains
of protein pocket-residues were re-oriented to accommodate
omeprazole and to optimize calculated interaction energies.
The cofactor, harmine as well as the water molecules were
removed from the two protein structures prior to docking.
Harmine defined the center of the pocket where omeprazole
was docked into MAO-A. Two binding pockets were defined for
docking to TPH1; 1) the cofactor pocket, defined by the center of
the cofactor in the crystal structure, and 2) the postulated
allosteric pocket, where the center of the docking grid box was
defined as the center of residues that form close contacts with
allosteric ligands as described by (Petrassi et al., 2017),
i.e., residues 190, 280, 283–286, 289, 293, 311–312, 315–316,
321, 330, 354, 376, 378–379, 382, and 386. Omeprazole is a
racemate of two stereoisomers which have been found to have a
pKa-value of 7.1, assigned to the dissociation of the protonated
pyridine nitrogen (Wu and Delamere, 1997). All four forms of
omeprazole were docked independently toMAO-A and TPH1 (to
both the active and the postulated allosteric site). To validate our
docking protocol, we redocked harmine to MAO-A, obtaining an
RMSD of 1.4 Å (Supplementary Figure S1).
Animal Studies and Drug Administration
Male CD-1mice (Janvier Labs, Le Genest-St-Isle, France), 3 months
of age were used. The animals in the different treatment groups
were matched for age. The University of Barcelona’s Committee on
Animal Use and Care approved the protocol. Animals were housed
and tested in compliance with the guidelines described in the Guide
for the Care and Use of Laboratory Animals (Clark et al., 1997) and
following the European Union directives (2010/63/EU), FELASA
and ARRIVE guidelines. All efforts were made to minimize animal
suffering and the number of animals used. All animals were housed
in groups of five in standard cages with ad libitum access to food
and water and maintained under a 12-h dark/light cycle (starting at
7:30 AM), 22°C temperature, and 66% humidity. Omeprazole was
dissolved in 10% DMSO, 50% polyethylene glycol (PEG)-400, and
40% physiological saline. Animals were randomized to receive
omeprazole (10 mg/ml) or vehicle, administered i. p. in a
volume of 10 µL/g of animal bodyweight, resulting in a dose of
100mg/kg. Animals received vehicle (n  22) or omeprazole (n 
24) once daily for four consecutive days. While all treated animals
were tested in the tail suspension test, brain tissue from eight of the
vehicle-treated and nine of the omeprazole-treated mice was used
for subsequent analysis of 5-HT content. Serum samples for 5-HT
analysis were drawn from another nine vehicle-treated and eight
omeprazole-treated mice.
Tail Suspension Test
Immobility time in the tail suspension test is known to be
sensitive to manipulations that alter brain 5-HT content
(Garcia-Miralles et al., 2016; Palucha-Poniewiera et al., 2017).
Animals were subjected to the tail suspension test 20 h after the
last administration of vehicle or omeprazole. By use of surgical
tape, a cotton thread was affixed to the mouse tail, 1.5 cm from
the tip. The cotton thread was fastened to a horizontal metal bar,
leaving the mouse suspended in the air, 20 cm above the floor of a
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cage containing sawdust. Each animal was suspended for 6 min
and the time spent immobile during suspension was counted
using a stopwatch. Immobility time was defined as the absence of
movements of limbs or trunk. Thus, movements of the head
alone, such as sniffing, or swinging, pendulum-like motion of the
animal resulting from previous bouts of activity, were not
considered as mobility. The Mann-Whitney test was used for
statistical comparison of immobility time between vehicle- and
omeprazole-treated animals.
Sample Preparation and High Performance Liquid
Chromatography-MS/MS Determination of 5-HT
Levels in Brain and Serum
Serum Harvesting
Mice were rapidly sacrificed by cervical dislocation and whole
blood was obtained by cardiac puncture, collected in clean
polypropylene tubes and placed on ice. Serum was prepared
by centrifuging the whole blood samples at 15,600 relative
centrifugal force (rcf) and 4°C for 20 min. Subsequently, 10 µL
serum were mixed with 37.5 µL of TCA (trichloroacetic acid)
30%, 82.5 µL of H2O, and 10 µL of 5-HT-d4 (100 ng/ml sc-
473411, Santa Cruz Biotechnology, Dallas, TX). Samples were
vortexed for 1 min and incubated overnight at −80°C. Finally,
samples were centrifuged at 15,600 rcf and 4°C for 20 min and the
supernatants were stored at −80°C until analysis.
Brain Homogenates
Mice were rapidly sacrificed by cervical dislocation and one brain
hemisphere from each animal dissected in 1 ml of ice-cold H2O
and homogenized in a 1 ml Potter-Elvehjem glass tube using a
homogenizer-stirrer (HS-30E; Witeg Labortechnik GmbH,
Wertheim, Germany) with 10 strokes at 700–900 rotations per
min. 10 µL of the homogenate was mixed with 10 µL of
acetonitrile (Sigma-Aldrich) containing 2% CH3COOH
(Sigma-Aldrich), 150 µL of H2O and 10 µL of 5-HT-d4
(100 ng/ml sc-473411, Santa Cruz Biotechnology). Samples
were vortexed for 1 min and incubated overnight at −80°C,
after which samples were centrifuged at 15,600 rcf and 4°C for
20 min. The supernatants were stored at −80°C until analysis.
Quantitative Analysis of 5-HT
Quantitative analysis of 5-HT was carried out by liquid
chromatography coupled with tandem mass spectrometry (LC-
MS/MS) using an Agilent 1,290 Infinity UHPLC chromatograph
(Santa Clara, CA) coupled to a 6500 QTRAP mass spectrometer
(ABSciex, Framingham, MA) equipped with an Ion Drive Turbo
V ion source operating in positive ion mode. The column used
was an Acquity HSS T3 1.8 µm (50 × 2.1 mm) at 40°C;
autosampler temperature, 4°C; injection volume, 3 μL; flow
rate, 0.6 ml m in−1. Mobile phase was A) Ultrapure water with
0.1% HCOOH and B) Acetonitrile with 0.1% HCOOH. The
gradient program was as follows (t (min), %B) (0, 2), (0.5, 2),
(2, 10), (6, 50), (6.2, 95), (7, 95), (7.1, 21), (10, 2). Mass
spectrometry detection was performed by using the multiple
reaction monitoring (MRM) mode using the following
parameters: ion spray voltage, +5500 V; source temperature,
600°C; curtain gas, 20 psi; ion source gas 1 and gas 2, 50 and
50, respectively; collision-activated dissociation gas, High;
entrance potential (+/−)10 V. The MRM transitions for 5-HT
were 177/160 (Declustering potential DP 20V and collision
energy CE15V) for quantitative purposes and 177/115 (DP
20V, CE 37V) for confirmation purposes. 5-HT-d4 was used
as internal standard with a transition of 181/164 (DP 20V, CE
15V). Sample-to-sample differences in recovery, liquid handling,
and ionization efficiency were compensated for by normalizing to
the amount of 5-HT-d4 detected in the samples. Analyst 1.6.2
Software was used for data acquisition and Multi Quant 3.0.1 for
data processing; both from ABSciex (Framingham, MA).
A calibration curve was constructed with 5-HT standard
solutions between 0.3 and 73.5 nM (brain) or 156–7,364 nM
(serum) diluted in acetonitrile with 2% CH3COOH. Linear
regression was adjusted (1/x or 1/x2) in order to have
accuracies between 80 and 120% for all the 5-HT standards. 5-
HT concentrations were normalized to the mean concentration in
samples from vehicle-treated animals. Student’s t-test was used
for statistical comparison of 5-HT content between vehicle- and
omeprazole-treated animals.
Data Analysis
The influence of a test compound over the thermal stability of
TPH1 was determined as the change in melting temperature, Tm
(ΔTm  Tm − Tm/ref ), in the presence of 200 µM of the
compound. Tm/ref is defined as the melting temperature in the
presence of vehicle (2% DMSO). GraphPad Prism (version 8; La
Jolla, CA, USA) was used for analyzing enzyme inhibition data.
The following Eq. 1 was fitted to the data using nonlinear
regression, yielding an estimate of the IC50:
Y  bottom + (Top − Bottom)/(1 + 10X−logIC50) (1)
where Y is the response as a fraction of 1, X is the logarithm of
ligand concentration, Top is the maximum response and Bottom
is the minimum response in the presence of ligand.
Relative inhibition of MAO-A was calculated as a percentage
using the following Eq. 2:
%Relative inhibition  ((Slope of EC − Slope of S)/
Slope of EC) × 100 (2)
The slopes for all samples, either containing Enzyme Control
(EC) or test substance (S), were calculated by dividing the net
change in relative fluorescence units (ΔRFU; RFU2–RFU1) by the
time interval (Δt; t2 –t1).
In vitro assay data are presented as means ± SEM in the Figures
and as means and their 95% confidence intervals in the Tables.
RESULTS
Identification of Omeprazole as a
Tryptophan Hydroxylase 1 Binder
As TPH1 is responsible for the majority of 5-HT production in
peripheral tissues, we were primarily interested in finding new
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TPH1 inhibitors, rather than TPH2 inhibitors, due to the
potential usefulness of the former in treating dysregulation of
peripheral 5-HT. We identified omeprazole, a proton pump
inhibitor, as a TPH1 binder through HTS of the Prestwick
library using DSF detection as described recently (Betari et al.,
2020). The shift in midpoint denaturation temperature, ΔTm, was
measured in the presence of the various compounds in the
Prestwick library in order to find drugs altering the thermal
stability of TPH1. The Tm of TPH1 was measured by monitoring
the fluorescence intensity of a dye, SYPRO orange, the
fluorescence of which increases upon interaction with
hydrophobic parts of the denatured protein. Hits were
identified by determining ΔTm (ΔTm  Tm − Tm/ref ). Under
control conditions in the presence of 2% DMSO, the
denaturation temperature (Tm/ref) was 51.8 ± 0.47°C, as
recently described (Betari et al., 2020). Compounds which
induced a positive ΔTm were considered TPH1 stabilizers,
whereas compounds which produced a negative ΔTm were
taken to be destabilizers. Among the preliminary hits of the
Prestwick library, 37 compounds which stabilized TPH1 with a
ΔTm ≥ 3°C or destabilized TPH1 with ΔTm ≤ −3°C were chosen
for validation and further investigation in concentration-
response DSF experiments. Finally, we employed a TPH
activity assay using HPLC with fluorimetric detection to
quantify the product, 5-OH-Trp. The effects of 37
preliminary hit compounds on the activity of TPH1 were
tested at a concentration of 100 µM. Only four compounds
(shown in Figure 1); triclabendazole, omeprazole, nilvadipine,
and flumequine, reduced TPH1 activity by more than 50% and
were subjected to IC50 determination. Omeprazole reduced the
activity of TPH1 with an IC50 of 3.09 (95% confidence interval;
2.53–3.77) µM, whereas triclabendazole, nilvadipine, and
flumequine showed inhibition with very low potency (IC50
∼100 µM).
Effect of Omeprazole Analogues on
Tryptophan Hydroxylase 1 and Tryptophan
Hydroxylase 2 Enzymatic Activity
Following up on the discovery of omeprazole as a TPH1 inhibitor,
enzymatic assays of both TPH1 and TPH2 activity were used to
investigate the effect of several proton pump inhibitors;
esomeprazole, ilaprazole, lansoprazole, R-lanzoprazole,
pantoprazole, rabeprazole, and tenatoprazole, which are
structural analogues of omeprazole. pCPA and LP533401 were
used as reference inhibitors of these two enzymes (Betari et al.,
2020). Omeprazole showed inhibitory potency at TPH2 IC50 
4.30 (95% confidence interval; 2.78–6.87) µM similar to that at
TPH1 (Table 1). Ilaprazole was revealed to be the most potent
TPH inhibitor, with an IC50 of 0.83 (95% confidence interval;
0.64–1.8) µM at TPH1 and an IC50 of 0.535 (95% confidence
interval; 0.39–0.73) µM at TPH2, while esomeprazole,
tenatoprazole, and rabeprazole inhibited TPH1 and TPH2
with potencies similar to omeprazole. Pantoprazole,
lansoprazole, and (R)-lansoprazole were 6-fold less potent
inhibitors of TPH1 than omeprazole, but their potencies were
in the same range as omeprazole at TPH2. The effects of these
proton pump inhibitors on TPH1 and TPH2 are summarized in
Table 1; Figure 2.
FIGURE 1 | Primary hits identified using DSF. Molecular structure of primary hits identified through HTS using DSF detection and followed by enzymatic activity
assay at a final concentration of 100 µM of each tested compound.
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Kinetic Characterization of Tryptophan
Hydroxylase 1 Inhibition by Omeprazole
We chose to focus our further investigation on omeprazole, since
it is the most widely used of the proton pump inhibitors. Human
doubly truncated TPH1 (ΔNH102-ΔCOOH402) was used for
kinetic protein-ligand interaction studies. The enzyme assays
were performed as described above. The mechanism of action
of omeprazole at TPH1 was investigated by measuring TPH1
inhibition at different concentrations of omeprazole, L-Trp
substrate, and tetrahydrobiopterin (BH4) cofactor. Kinetic
TABLE 1 | Inhibitory activities of omeprazole and its analogues at TPH1 and TPH2, and MAO-A. 1% DMSO was included as a vehicle control.
Name Structure TPH1 IC50/µM TPH2 IC50/µM MAO-A IC50/µM
pCPA 11.25 (7.11–17.84) 5.34 (3.23–8.19) —
LP533401 0.41 (0.31–0.53) 0.08 (0.05–0.13) —
Omeprazole 3.09 (2.53–3.77) 4.30 (2.78–6.87) 89.42 (57.48–141.4)
Esomeprazole 3.76 (3.02–4.67) 2.15 (1.62–2.85) 17.97 (9.15–34.65)
Tenatoprazole 2.16 (1.80–2.60) 4.90 (3.61–6.73) 29.18 (18.02–48.17)
Rabeprazole 7.57 (5.47–10.56) 2.13 (1.52–3.01) 12.80 (8.02–20.6)
Pantoprazole 21.68 (9.67–51.83) 8.20 (5.42–12.56) 461.9 (271.0–908.5)
Lansoprazole 24.60 (18.43–33.25) 5.21 (3.19–8.56) 250.7 (159.4–415.9)
(R)-lansoprazole 18.80 (14.81–24.04) 3.36 (1.18–8.96) 137.3 (90.83–211.8)
Ilaprazole 0.83 (0.64–1.8) 0.53 (0.39–0.73) 28.96 (17.16–49.08)
IC50 inhibitory concentration (μM) are shown for omeprazole and its analogues. pCPA and LP 533401 were used as reference compounds for TPH1 and TPH2 inhibition. Data represent
means of three independent experiments, each performed in duplicate. Values in brackets represent 95% confidence intervals.
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FIGURE 2 | Inhibitory activities of omeprazole and its analogues on TPH1 and TPH2. In vitro enzyme activity assays were used to evaluate the effect of proton pump
inhibitors to inhibit tryptophan hydroxylase 1 (TPH1); tryptophan hydroxylase 2 (TPH2). Data represent means ± SEM of three separate experiments performed in
duplicate.
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parameters for both L-Trp and BH4 were calculated by fitting the
Michaelis-Menten equation to the data using nonlinear
regression, in the absence and presence of different
concentrations of omeprazole (1, 10, and 100 µM). When
enzyme activity was measured as a function of substrate
(L-Trp) concentration (0.625–20 µM), the concentration of the
cofactor (BH4) was fixed at 200 µM. As shown in Table 2 and
Figure 3A, there was a progressive decrease in Vmax whereas KM
remained essentially unchanged with increasing concentrations
of omeprazole. Likewise, when enzyme activity was measured as a
function of co-factor concentration (2.4–200 µM) in the presence
of a fixed concentration of L-Trp (20 µM), a decreasing Vmax and
a similar KM was again observed as the omeprazole concentration
was increased (Table 2; Figure 3B). These results suggest that
omeprazole is a non-competitive inhibitor, both with respect to
L-Trp and to BH4.
Omeprazole Characterization-Effects on
the Other Aromatic Amino Acid
Hydroxylases
The potency of omeprazole as a TPH1 inhibitor was compared
to those of the benchmark TPH1 inhibitors, pCPA and LP
533401 (data shown in Table 1). The selectivity of omeprazole
to inhibit TPH1 over the other aromatic amino acid
hydroxylases was also investigated. As described above,
omeprazole inhibited TPH2 with similar potency as TPH1.
However, no inhibition of PAH or TH was observed up to a
concentration of 100 µM (Figure 4). Thus, omeprazole
inhibition of TPH1 and TPH2 was highly selective over the
two other aromatic amino acid hydroxylases, PAH and TH.
Finally, the inhibitory potency of omeprazole at full-length
TPH1 was studied and found to be virtually identical to that
observed in experiments with doubly truncated TPH1
(Supplementary Figure S2).
TABLE 2 | Enzyme kinetic parameters of tryptophan hydroxylase one in the absence and presence of omeprazole.
[Omeprazole] (µM) Vmax (µmol/min/mg) KM (µM)
(A) L-Trp (0.625–20) µM BH4 200 µM 0 26.23 (24.35–28.12) 1.90 (1.43–2.38)
1 24.96 (23.18–26.74) 2.24 (1.71–2.77)
10 21.08 (18.84–23.32) 3.61 (2.51–4.72)
100 7.03 (6.07–7.98) 2.05 (1.10–2.99)
(B) BH4 (2.4–200) μM L-Trp 20 µM 0 48.36 (45.94–50.78) 13.66 (11.09–16.24)
1 39.93 (37.18–42.69) 20.40 (15.57–25.25)
10 31.06 (28.90–33.21) 25.55 (19.77–31.33)
100 21.11 (18.96–23.26) 32.43 (22.3–42.55)
(A) TPH1 activity was measured as a function of L-Trp concentration in the absence (DMSO vehicle) or presence of omeprazole (at 1, 10, and 100 µM) and 200 µM BH4. (B) TPH1 activity
was measured as a function of BH4 concentration in the absence (DMSO vehicle) or presence of omeprazole (at 1, 10, and 100 µM) and 20 μM L-Trp. Values in brackets represent 95%
confidence intervals for the fit of the Michaelis–Menten equation to data.
FIGURE 3 |Mechanism of TPH1 inhibition by omeprazole. TPH1 inhibition by omeprazole in the presence of varying concentrations of the substrate; L-Trp (A), or
cofactor; BH4 (B). The Michaelis-Menten equation was fitted to data using nonlinear regression. The fits are consistent with a decrease in Vmax with increasing
concentrations of compound, while KM remained virtually unchanged.
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Effect of Omeprazole and Its Analogues on
Monoamine Oxidase-A Enzymatic Activity
The effects of omeprazole, esomeprazole, ilaprazole, lansoprazole,
R-lanzoprazole, pantoprazole, rabeprazole, and tenatoprazole on
MAO-A enzymatic activity were tested using a fluorescence-
based MAO-A activity assay measuring the formation of H2O2
as a byproduct of the enzymatic activity (Figure 5).
Docking Studies of Omeprazole Binding to
Tryptophan Hydroxylase1 and Monoamine
Oxidase-A
The protonated S-stereoisomer of omeprazole was predicted to
have the highest binding affinity to both MAO-A and TPH1,
considering both the active site of TPH1 (Figure 6A) and its
previously described allosteric site (Petrassi et al., 2017).
Omeprazole overlaps with the binding site of the known
inhibitor, harmine, present in the original crystal structure
(Son et al., 2008), when docked to MAO-A (Figure 7).
Omeprazole was predicted to have higher affinity for MAO-A
than for TPH1, and to have a slight preference for the allosteric
site over the active site in TPH1 (Table 3).
In vivo Studies
Omeprazole has commonly been administered i. p. to mice at
doses of 20–150 mg/kg (Cowan et al., 2005). We were interested
in finding out how the seemingly opposing actions of omeprazole,
as a TPH inhibitor on the one hand and an MAO-A inhibitor on
the other, might affect its in vivo profile. We thus administered
omeprazole (100 mg/kg, i. p.) to mice once daily for four days.
Twenty hours after the last dose, animals were subjected to the tail
suspension test; a behavioral readout which is sensitive to CNS 5-
HT levels and commonly used to assess antidepressant-like
activity of experimental compounds. Compared to vehicle
controls, mice receiving omeprazole spent significantly less
time immobile during the 6 min tail suspension trial (p 
0.028, Mann-Whitney test; Supplementary Figure S3).
For analysis of brain and serum 5-HT content, the animals
were sacrificed by cervical dislocation immediately after
behavioral testing and brain tissue and serum were harvested.
Omeprazole-treated animals displayed significantly higher 5-HT
content in both brain (Figure 8A) and serum (Figure 8B)
compared to vehicle controls.
DISCUSSION AND CONCLUSION
In the present investigation, we showed that the proton pump
inhibitor, omeprazole, as well as several analogues, inhibit
TPH1 and TPH2 with low micromolar potency. Omeprazole
was the first proton pump inhibitor when approved for clinical
use in 1988 (Lindberg and Carlsson, 2006). It has been
designated an essential medicine by the World Health
Organization, was the most commonly prescribed drug in the
United States in 2017 and can be obtained without a
prescription in many countries (WHO, 2019). Although, for
example, ilaprazole showed higher potency to inhibit TPH1, we
chose to focus our further investigative efforts on omeprazole,
given its widespread use.
Kinetic measurements of omeprazole inhibition of TPH1
suggest that omeprazole binds in a noncompetitive fashion
with respect to both the cofactor and the substrate. This may
suggest that omeprazole does not bind to the tryptophan or
cofactor binding sites, but rather to an allosteric site in the
protein. Our computational docking results are also
compatible with an allosteric mode of action (see below).
Allosteric TPH1 inhibitors are of potential interest for further
development, as such ligands can be expected to bind outside the
conserved active site and thus, potentially, show greater selectivity
between the different aromatic amino acid hydroxylases. Selective
TPH1 inhibitors are of interest from a medicinal chemistry
perspective, since elevated peripheral 5-HT is an important
component of several disease conditions, such as carcinoid
syndrome; a malignancy-related hyperserotonergic state
characterized by severe diarrhea, as well as irritable bowel
syndrome and infectious and autoimmune states associated
with gut inflammation, including inflammatory bowel disease
(Manocha and Khan, 2012; Margolis et al., 2014; Kim et al., 2015).
TPH1 inhibitors with potencies in the nanomolar range have
been reported by Lexicon Pharmaceuticals, out of which one
compound, telotristat, was recently approved for treatment of
carcinoid syndrome (Jin et al., 2009; Ouyang et al., 2012). The
Lexicon compounds, however, are orthosteric inhibitors
structurally related to pCPA and behave, as expected,
competitively with regards to the substrate (Cianchetta et al.,
FIGURE 4 | Selectivity of omeprazole to inhibit TPH1 over other aromatic
amino acid hydroxylases. In vitro enzyme assays were used to evaluate the
selectivity of omeprazole to inhibit TPH1 over the other aromatic amino acid
hydroxylases; TPH2, TH, and PAH. TPH1, doubly truncated tryptophan
hydroxylase 1 (ΔNH102-ΔCOOH402); TPH2, tryptophan hydroxylase two;
PAH, phenylalanine hydroxylase, TH tyrosine hydroxylase. The data are
expressed as means ± SEM; from three independent experiments, each
performed in duplicate.
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2010). We recently reported the benzisothiazolinone, PBIT, and
two related compounds, as TPH inhibitors with similarly non-
competitive actions at TPH1(Betari et al., 2020) These
compounds displayed excellent selectivity toward TH, similar
to omeprazole, but showed some inhibition of PAH at high
micromolar concentrations.
As already mentioned, the similarity between the active sites of
the two TPH isoforms, TH, and PAHmeans that achieving ligand
specificity has been difficult. This fact has therapeutic
implications, since off-target inhibition of PAH may
potentially lead to neurotoxic accumulation of its substrate,
phenylalanine. It is therefore noteworthy that the inhibitory
effect of omeprazole was highly specific for TPH1 and TPH2
over both TH and PAH, with virtually no inhibition observed at
the latter two enzymes at concentrations up to 100 µM.
Elaboration of the proton pump inhibitor scaffold may thus be
of relevance for future studies, in order to develop more potent
TPH inhibitors devoid of activity toward TH and PAH.
Esomeprazole, the S-enantiomer of omeprazole, was recently
shown to display high micromolar potency in inhibiting MAO-A
FIGURE 6 | Docking of omeprazole to TPH1. (A) Docking of omeprazole to the active site of TPH1. Omeprazole is shown in ball and stick representation with
carbons colored gray while the biopterin cofactor is shown in sticks with green carbons. The active site iron is shown as an orange sphere. Superimposed is also the
inhibitor from Lexicon Pharmaceuticals (LP-521834) in sticks with yellow carbons. Omeprazole partially overlaps with the binding pockets of both the cofactor and LP-
521834 when docked to the active site of TPH1. (B) Docking of omeprazole to the postulated allosteric site of TPH1. Omeprazole (shown as ball and sticks) docks
close to the surface of the postulated allosteric pocket of TPH1, near the four phenylalanines defining the entrance of the site (F286, F289, F330 and F379), shown as
green sticks in the figure.
FIGURE 5 | Inhibitory activities of omeprazole and its analogues at MAO-A. In vitro enzyme activity assays were used to evaluate the potencies of omeprazole and
its analogues to inhibit monoamine oxidase-A (MAO-A). Data represent means ± SEM of three separate experiments.
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(Petzer et al., 2013). We validated this finding by testing
omeprazole and its analogues in an MAO-A inhibition assay.
While esomeprazole showed the expected inhibitory potency
with an IC50 of 17.97 (95% confidence interval;
9.15–34.65) µM (compared to 23 µM in Petzer et al., 2013),
racemic omeprazole was somewhat less potent with an IC50 of
89.42 (95% confidence interval; 57.48–141.4) µM. Among the
other proton pump inhibitors tested, rabeprazole was the most
potent with an IC50 of 12.80 (95% confidence interval;
8.02–20.6) µM and pantoprazole the least potent with an IC50
of 461.9 (95% confidence interval; 271.0–908.5) µM.
The potency of proton pump inhibitors at their therapeutic
target, the gastric H+/K+-ATPase, is reportedly in the low
micromolar range and thus similar to the IC50 s at TPH1 and
TPH2 observed in the present study (Beil et al., 1992). In
particular, given that many studies in mice have been
conducted with proton pump inhibitors doses ranging from 20
to 150 mg/kg (Cowan et al., 2005; Fontecha-Barriuso et al., 2020),
the in vivo actions of these compounds at both TPH1/2 and
MAO-A should also be considered.
In agreement with our experimental findings, docking studies
indicate that the protonated S-enantiomer of omeprazole,
esomeprazole, has the highest binding affinity for both TPH1
and MAO-A. Omeprazole overlaps with the binding of the
known MAO-A inhibitor, harmine, in MAO-A and is
estimated to have similar binding affinities to the active site
and the allosteric binding site (Petrassi et al., 2017) of TPH1.
When docked to the active site of TPH1, omeprazole partly
occupies the cofactor and substrate binding pocket (LP-521834
demonstrates a similar binding mode). The docking results are
not decisive in which of the two TPH1 pockets, the active site or
the allosteric site, is the most favorable for omeprazole to interact
with. However, as omeprazole inhibits TPH1 in a non-
competitive manner, it would seem more likely to interact
with TPH1 outside of the active site.
Use of proton pump inhibitors has been associated with a higher
incidence of clinical depression (Huang et al., 2018; Laudisio et al.,
2018), which may be congruent with 5-HT depletion resulting from
the TPH2 inhibitory action observed in the present study. On the
other hand, MAO-A inhibitors are used clinically for their
antidepressant actions, presumably mediated via 5-HT elevation.
In order to explore the net in vivo effect of these presumably
opposing actions on 5-HT metabolism, we administered
omeprazole i. p. to mice at a dose of 100 mg/kg for four
consecutive days. Somewhat surprisingly, given the lower in vitro
potency of omeprazole at MAO-A compared to TPH1/2,
omeprazole-treated animals had significantly higher 5-HT levels
both in serum and in whole-brain tissue relative to vehicle-treated
controls. In agreement with a positive effect on brain 5-HT levels,
mice treated with omeprazole spent significantly less time immobile
in the tail suspension test, compared to control mice. Thus, it
appears that, at least at the dose used in the present study, the net
outcome of the opposing effects of omeprazole is to increase 5-HT
in vivo. In this context, it is interesting to note that there has been a
recent case report of serotonin syndrome in a patient receiving
omeprazole in combination with the SSRI, citalopram
(Tsamatsoulis et al., 2018), which would be congruent with the
MAO-A inhibition described here and by (Petzer et al., 2013). Thus,
omeprazole may have different effects on the 5-HT system
depending on dose and co-administration of other serotonergic
drugs. As mentioned above, besides its central actions, 5-HT has a
FIGURE 7 | Docking of Omeprazole to MAO-A. The docking pose of
omeprazole with the highest docking score is shown with in ball and stick with
gray carbons. Also shown is the binding pose of harmine in sticks with green
carbons. The docking pose of omeprazole overlaps entirely with harmine
in the binding pocket of MAO-A.
TABLE 3 | Docking score (estimated binding affinities) of omeprazole and harmine
to TPH1 and MAO-A.
TPH1-active site TPH1-allosteric site MAO-A
Omeprazolea −8.2 −8.6 −11.1
aS-isomer of protonated omeprazole. Docking score is a crude estimate of the free
energy of binding. The more negative docking score, the higher the predicted binding
affinity.
FIGURE 8 | In vivo effects of 100 mg/kg omeprazole on 5-HT levels. 5-
HT contents, as determined by LC-MS, in whole-brain tissue (A; vehicle, n  8;
omeprazole, n  9) and serum (B; vehicle, n  9; omeprazole, n  8) in mice
treated with omeprazole (100 mg/kg, i. p.) or vehicle once daily for
4 days *, p < 0.05; ***, p < 0.001, Student’s t-test.
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prominent role in exacerbating gut inflammation (Manocha and
Khan, 2012; Margolis et al., 2014; Kim et al., 2015) and proton
pump inhibitor-mediated actions at TPH1 and MAO-A could thus
have either beneficial or detrimental consequences, depending on
the net effect on local 5-HT concentrations. For example, when
administered for the treatment of Helicobacter pylori-related ulcers
or gastroesophageal reflux disease (Herszenyi et al., 2020), TPH1
inhibition might be expected to reduce inflammation through a
reduction of 5-HT in the gastrointestinal mucosa, whereas MAO-A
inhibition would produce an opposite, potentially pro-
inflammatory effect.
The 5-HT found in blood (both in serum and in platelets) is
mainly produced by the enterochromaffin cells in the gut and
taken up by platelets via the 5-HT transporter (SERT). It could be
hypothesized that SERT blockade, rather than MAO-A
inhibition, would be responsible for the elevation of serum 5-
HT observed here. While we have not assessed any such putative
actions of omeprazole on SERT in the present work, several
previous observations argue against this possibility. SERT KO
mice show virtually undetectable levels of 5-HT in blood (Chen
et al., 2001) and while acute administration of SERT blockers
transiently (4 h) elevated plasma 5-HT, subchronic (7 or 14 days)
treatment with SERT blockers did not modify plasma 5-HT
(Ortiz and Artigas, 1992), suggesting that 5-HT released from
the enterochromaffin cells is effectively degraded or removed if
not taken up by platelets. Degradation by MAO-A located in the
liver and vascular endothelial cells would be a likely mechanism
for 5-HT removal (Ortiz and Artigas, 1992). Furthermore, the
total tissue content of brain 5-HT (as measured here) has been
found to be decreased in SERT KO rats (Homberg et al., 2007).
In contrast, subchronic administration of the MAO-A
inhibitor, clorgyline, increased plasma 5-HT levels (Garcia-
Miralles et al., 2016). Thus, while caution is always warranted
when extrapolating in vitro data to the in vivo situation, we would
tend to speculate that the increase in blood and brain 5-HT
content observed here following subchronic treatment with
omeprazole is most likely a consequence of MAO-A
inhibition. Finally, while we have not studied the involvement
of 5-HT receptors in the actions of omeprazole, 5-HT2B receptors
are also known to play a role in the regulation of plasma 5-HT
levels (Callebert et al., 2006).
The tail suspension test was used here because it is known to be
sensitive to manipulations which alter brain 5-HT content
(Garcia-Miralles et al., 2016; Palucha-Poniewiera et al., 2017).
However, in the context of translatability it should be pointed out
that use of this single behavioral test is a limitation of the present
study and that the use of additional paradigms (such as the forced
swim test, or genetic- or chronic stress models of depression)
would be necessary in order to firmly establish an antidepressant-
like effect of omeprazole (Wang et al., 2017). Furthermore, such
antidepressant-like effects are not only influenced by brain 5-HT
content, but is a consequence of extracellular (rather than whole
brain) 5-HT and the activation states of multiple subtypes of 5-
HT receptors (Pytka et al., 2016b) as well as of other
neurotransmitter receptors (Pytka et al., 2016a). Thus, the fact
that we have not studied any potential effect of omeprazole on 5-
HT receptors is a further limitation of the present work.
In summary, omeprazole and other structurally related proton
pump inhibitors reduced the catalytic activity of TPH1 and TPH2 in
the lowmicromolar range, whereas MAO-A inhibition was observed
at higher micromolar concentrations. Interestingly, omeprazole did
not appreciably inhibit TH nor PAH at concentrations as high as
100 µM. When administered at 100mg/kg, omeprazole increased 5-
HT concentrations in serum and brain tissue and decreased
immobility time in the tail suspension test. Serotonergic actions
should thus be considered when evaluating the in vivo effects of
proton pump inhibitors. Interestingly, some of these compounds
appeared to have quite different relative potencies against TPH1,
TPH2, andMAO-A (Table 1; Figure 2; Figure 5). This indicates that
it may be possible to developmore selective inhibitors targeting either
one of the TPH isoforms, using the proton pump inhibitor scaffold as
a point of departure. Future investigations of the structure-activity
relationships of proton pump inhibitor-like scaffolds at TPH1, TPH2,
and MAO-A may result in new TPH inhibitors with increased
selectivity over TH and PAH.
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